Mymetics announces publication in npj - Vaccines “New GMP manufacturing processes to obtain thermostable HIV-1 gp41 virosomes under solid forms for various mucosal vaccination routes”

Epalinges, Switzerland, 18 May 2020 – Mymetics Corporation (OTCQB: MYMX), a pioneer in the research and development of virosome based vaccines and immunotherapies against human life disabling and infectious diseases, announced today a publication in Nature Partner Journals “Vaccines” describing the results from a new GMP manufacturing process to obtain thermostable HIV-1 gp41 virosome vaccines under solid forms and various mucosal vaccination routes

Media Name Media Type Description Download
Article PDF Download